Patent ID: 7141546

Claim:
A CRFR2 ligand, or a pharmaceutically acceptable salt thereof, which ligand exhibits CRF antagonistic properties and binds selectively to CRFR2 and which has the amino acid sequence: Y-R 8 -R 9 -R 10 -R 11 -R 12 -R 13 -R 14 -Arg-R 16 -Nle-R 18 -R 19 -R 20 -R 21 -R 22 -R 23 -R 24 -R 25 -R 26 -R 27 -R 28 -Gln-R 30 -R 31 -R 32 -R 33 -R 34 -R 35 -R 36 -R 37 -R 38 -R 39 -R 40 -NH 2 wherein Y is H or an acyl group having up to 7 carbon atoms or radioiodinated tyrosine; R 8 is Asp or des-R 8 ; R 9 is Leu or des-R 9 ; R 10 is Ser, Thr or des-R 10 ; R 11 is D-Phe, D-Leu, D-Tyr, D-Cpa, D-Nal, D-Pal, Phe, Leu, Tyr, Cpa, Nal or Pal; R 12 is His or Glu; R 13 is CML or Leu; R 14 is Leu or CML; R 16 is Glu, CML or Lys; R 18 is Leu, CML, Ile, Ala or Aib; R 19 is Glu, D-Glu or His; R 20 is Ile or Leu; R 21 is Ala, D-Ala, Aib, Thr, D-Thr, Glu or D-Glu; R 22 is Arg or Lys; R 23 is Gln or Ala or Aib; R 24 is Glu or Asp; R 25 is Lys or Gln; R 26 is Glu, Leu or CML; R 27 is Lys, Ala or Aib; R 28 is Gln or Glu; R 30 is Ala or Aib; R 31 is Glu or Gln; R 32 is Asn or Ser; R 33 is Asn or Aib; R 34 is Lys, Lys(Ac) or Orn; R 35 is Leu or Ile; R 36 is CML or Leu; R 37 is Leu or Nle; R 38 is Asp or Glu; R 39 is CML, Ile or Leu; and R 40 is Ile, Ala, Gly, Val, Leu, Nle, Phe, Nva or Gln; wherein a cyclizing bond may exist between the side chains of R 31 and R 34 so as to form a cyclo(31–34) structure.